Expand your knowledge in the diagnosis and treatment of the most infrequent cancers, especially those related to the chest wall and head and neck. You will advance in your profession and achieve better results in your patients"

The most recent studies on head and neck tumors, as well as those of the thoracic wall, have shown that professionals must be trained and updated to face the new challenges posed by the sector. Therefore, it is essential to deepen in this field, identifying diagnostic techniques and effective treatments. That is why this Postgraduate certificate will provide all the information that professionals need so much.

On the other hand, during the completion of this program, the student will gain the experience of the multitude of clinical cases that are presented, and will acquire skills in aspects of epidemiology, etiology and pathogenesis, clinical presentation, diagnosis and classification, prognostic factors, treatment and recommendations of clinical guidelines.
  
Additionally, the professional will have a section dedicated to lung cancer as a paradigm of personalized medicine and will acquire skills in the use of diagnostic techniques and new treatment options. They will also be able to take a tour through the known driver mutations  in the context of lung cancer: EGFR, BRAF, MET, KRAS, ALK, ROS-1. And you will learn about the role of translocations and rearrangements or amplifications:   NTRK, RET, MET, HER-2.  

Finally, students will take a tour of the most infrequent tumors of the otorhinolaryngology and head and neck area, acquiring skills for their diagnosis and treatment: nasopharyngeal carcinoma and salivary gland tumors; nasal and paranasal sinus tumors; melanomas, sarcomas and lymphoproliferative syndromes of the head and neck; dental tumors; ameloblastoma and neuroendocrine tumors of the head and neck. 

The experts who belong to the teaching team of this program, all of them referents in each area of knowledge, will develop aspects related to the context of this spectrum of pathologies, will present the clinical and molecular vision of the same, will show their diagnostic and therapeutic approaches and will explain complementary aspects such as their research and institutional environment or the global reality of the patients who suffer from them.  

In addition, students will be able to complete the program at their own pace, without being subject to fixed schedules or the travel involved in classroom teaching, so they can combine it with the rest of their daily obligations.

Become an expert on driver mutations in the context of lung cancer: EGFR, BRAF, MET, KRAS, ALK, ROS-1"

This Postgraduate certificate in Tumors of the Pleura, Mediastinum and Chest Wall contains the most complete and up-to-date scientific program on the market. It’s most outstanding features are:

• Case studies presented by experts in oncology  
• The graphic, schematic and eminently practical contents with which they are conceived gather scientific and practical information on those disciplines that are essential for professional practice 
• News on this type of tumors 
• Practical exercises where the self-assessment process can be carried out to improve learning 
• Special emphasis on innovative methodologies in the approach to this type of tumors 
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection work
• Content that is accessible from any fixed or portable device with an Internet connection

The specialization of oncology professionals achieves improvements in the treatment of patients, so it is crucial to continue learning throughout your medical career" 

The teaching staff includes professionals from the Oncology sector, who bring their experience to this educational program, as well as renowned specialists from leading societies and prestigious universities. 

Its multimedia content, developed with the latest educational technology, will allow the professional a situated and contextual learning, that is, a simulated environment that will provide an immersive training programmed to train in real situations. 

The design of this program focuses on Problem Based Learning, 
through which the specialist must try to solve the different situations of professional practice that arise throughout the academic program. For this purpose, the professional will be assisted by an innovative interactive video system created by renowned and experienced experts. 

Become proficient in the use of diagnostic techniques and new treatment options for tumors of the Pleura, Mediastinum and Thoracic Wall"

This 100% online program will allow you to balalnce your studies with your professional work while increasing your knowledge in this field"

The syllabus of this program has been designed based on the requirements of medicine applied to the existence of certain tumors classified as rare, a specialization that is scarce in the educational market and of vital importance in health care. 
Therefore, it is essential that medical professionals delve deeper into the subject, contributing to the investigation of the conditions that cause these cases and propose treatments that minimize them. Therefore, the content of the program has been structured in ten topics that comprise all the information necessary for the student on their way to medical excellence.

This program delves into lung cancer as a paradigm of personalized medicine. You will delve into its diagnostic techniques and the role of liquid biopsy"

Module 1. Pleural, Mediastinal and Chest Wall Tumors: Lung cancer as a paradigm of the new rare, but not orphan,      tumors. Head and NeckCancer. 

1.1. Pleural Tumors: Mesothelioma

1.1.1. Introduction and Epidemiology
1.1.2. Etiology and Pathogenesis
1.1.3. Clinical Presentation
1.1.4. Diagnosis and Staging
1.1.5. Prognostic Factors
1.1.6. Treatment and Recommendations (Guidelines/Consensus)
1.1.7. Future Perspectives

1.2. Mediastinal Tumors: Thymoma and Thymic Carcinoma

1.2.1. Introduction and Epidemiology
1.2.2. Etiology and Pathogenesis
1.2.3. Clinical Presentation
1.2.4. Diagnosis and Staging
1.2.5. Prognostic Factors
1.2.6. Treatment and Recommendations (Guidelines/Consensus)
1.2.7. Future

1.3. Chest Wall Tumors

1.3.1. Introduction and Epidemiology
1.3.2. Etiology and Pathogenesis
1.3.3. Clinical Presentation
1.3.4. Diagnosis and Classification
1.3.5. Prognostic Factors
1.3.6. Treatment and Recommendations
1.3.7. Future

1.4. Pulmonary Neuroendocrine Tumor: Typical Carcinoid, Atypical Carcinoid, and Large Cell Carcinoma

1.4.1. Introduction and Epidemiology
1.4.2. Etiology and Pathogenesis
1.4.3. Clinical Presentation
1.4.4. Diagnosis and Classification
1.4.5. Prognostic Factors
1.4.6. Treatment and Recommendations
1.4.7. Future

1.5. Lung Cancer as a Paradigm for Personalized Medicine: Diagnostic Techniques and the Role of Liquid Biopsy

1.5.1. Introduction
1.5.2. Sample Types According to Diagnostic Approach
1.5.3. Sample Handling Optimization
1.5.4. Response Time and Report Characteristics
1.5.5. Tumor Heterogeneity: Role of Liquid Biopsy
1.5.6. Molecular Diagnostic Techniques: IHQ, FISH, RT-PCR, NGS
1.5.7. Guide Recommendations

1.6. Mutations: EGFR, BRAF, MET, KRAS

1.6.1. Introduction: Epidemiology, Patient Profile, Diagnostic Techniques and Brain Disease
1.6.2. Prognostic Factors
1.6.3. First-Line Targeted Therapy
1.6.4. Resistance Mechanisms
1.6.5. Second-Line Therapy and Successive Lines
1.6.6. Role of Chemotherapy +/- Immunotherapy
1.6.7. Future

1.7. Translocations: ALK, ROS-1

1.7.1. Introduction: Epidemiology, Patient Profile, Diagnostic Techniques and Brain Disease
1.7.2. Prognostic Factors
1.7.3. First-Line Targeted Therapy
1.7.4. Resistance Mechanisms
1.7.5. Second-Line Therapy and Successive Lines
1.7.6. Role of Chemotherapy +/- Immunotherapy
1.7.7. Future

1.8. Rearrangements/Amplifications: NTRK, RET, MET, HER-2

1.8.1. Introduction: Epidemiology, Patient Profile, Diagnostic Techniques and Brain Disease
1.8.2. Prognostic Factors
1.8.3. First-Line Targeted Therapy
1.8.4. Resistance Mechanisms
1.8.5. Second-Line Therapy and Successive Lines
1.8.6. Role of Chemotherapy +/- Immunotherapy
1.8.7. Future

1.9. Nasopharyngeal Carcinoma and Salivary Gland Tumors: Nasal and Paranasal Sinus Tumors

1.9.1. Nasopharyngeal Carcinoma

1.9.1.1. Introduction
1.9.1.2. Epidemiological Data
1.9.1.3. Etiology and Etiopathogenesis
1.9.1.4. Clinical Manifestations
1.9.1.5. Diagnostic Methods and Extension Diagnosis
1.9.1.6. Multidisciplinary Treatment

1.9.2. Salivary Gland Tumors

1.9.2.1. Major Salivary Gland Tumors
1.9.2.2. Minor Salivary Gland Tumors

1.9.3. Nasal and Paranasal Sinus Tumors

1.9.3.1. Epidemiology
1.9.3.2. Etiopathogeny, Histology and Natural History
1.9.3.3. Clinical, Diagnostic and Staging
1.9.3.4. Treatment

1.10. Melanomas, Sarcomas and Lymphoproliferative Syndromes of the Head and Neck: Rare Tumors. Ameloblastoma. Neuroendocrine Head and Neck Tumors

1.10.1. Head and Neck Melanoma

1.10.1.1. Etiologic, Epidemiologic and Clinical Factors
1.10.1.2. Diagnostic and Therapeutic Aspects
1.10.1.3. Special Presentations of Head and Neck Melanoma
1.10.2. Head and Neck Sarcomas
1.10.2.1. Etiopathogenesis and Epidemiology
1.10.2.2. Clinical Aspects
1.10.2.3. Diagnosis
1.10.2.4. Therapeutic Aspects

1.10.3. Lymphoproliferative Head and Neck Syndromes

1.10.3.1. Etiological Factors
1.10.3.2. Staging Procedures
1.10.3.3. Clinical Scheme of Lymphoid System Neoplasms

1.10.4. Dental Tumors

1.10.4.1. Odontogenic Tumor Classification

1.10.5. Ameloblastoma
1.10.6. Neuroendocrine Head and Neck Tumors

1.10.6.1. Neuroendocrine Carcinomas of Epithelial Origin
1.10.6.2. Atypical Carcinoid
1.10.6.3. Small Cell Neuroendocrine Carcinoma
1.10.6.4. Large Cell Neuroendocrine Carcinoma
1.10.6.5. Neuroendocrine Carcinoma of Neural Origin  

Quality content for a quality Students. TECH accompanies you on your path to excellence"